Evidence map›Paper›PMID 33933842›Full record

ReviewInternational immunopharmacology2021

The immunomodulatory mechanism of dexmedetomidine.

Koichi Yuki

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06993740 (The Effect of Dexmedetomidine Administration on the Success of Reconstructive Microsurgery in Cancer Patients), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06993740 nacompletednot on this mapstarted 2025, after this paper: background citation

The Effect of Dexmedetomidine Administration on the Success of Reconstructive Microsurgery in Cancer Patients: A Study of Glycocalyx Integrity, Inflammatory Response, Thrombosis, Angiogenesis, Oxidative Stress, and Tissue Microcirculation

TypeinterventionalSponsorDharmais National Cancer Center HospitalRan2025 to 2026Enrolled60ConditionsFlap Monitoring, Inflammation, Thrombosis, Oxidative StressArmsNaCl 0,9%, Dexmedetomidine
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Determination of Median Effective Concentration (ECDrug design, development and therapy · 2026
    Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Koichi YukiDepartment of Anesthesiology, Critical Care and Pain Medicine, Cardiac Anesthesia Division, Boston Children's Hospital, USA; Department of Anaesthesia, Harvard Medical School, USA; Department of Immunology, Harvard Medical School, USA. Electronic address: koichi.yuki@childrens.harvard.edu.
Boston Children's Hospital · US

Funding

The impact of anesthetic selection on sepsis outcome and its mechanismR01GM118277 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI YUKI, KOICHI · 2016 to 2020
$1.8M
Surgical site infections and the role of anesthesia and bacterial ion transportersR01GM127600 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI YUKI, KOICHI · 2020 to 2022
$1.1M
NIGMS NIH HHS R01 GM118277NIGMS NIH HHS R01 GM127600
6 · The paper itself

Abstract

Dexmedetomidine has been increasingly introduced into the perioperative care of surgical patients. Because a subset of anesthetics/sedatives are immunomodulatory, it is critical to understand the role of dexmedetomidine in our host immune functions. Here we reviewed the role of dexmedetomidine in different immune cells. We also reviewed published clinical articles that described the role of dexmedetomidine in organ injury, cancer surgery, and infection. In animal studies, dexmedetomidine attenuated organ injury. In clinical studies, dexmedetomidine was associated with an improvement in outcomes in cardiac surgery and transplant surgery. However, there is a paucity in research examining how dexmedetomidine is associated with these outcomes. Further studies are needed to understand its clinical application from immunological standpoints.

Indexed as

Adrenergic alpha-2 Receptor AgonistsAnimalsDexmedetomidineDisease Models, AnimalHumansImmunologic FactorsInflammation MediatorsLeukocytesPerioperative PeriodReceptors, Adrenergic, alpha-2Stress, PhysiologicalSurgical Procedures, OperativeAdrenergic alpha-2 Receptor AgonistsDexmedetomidineImmunologic FactorsInflammation MediatorsReceptors, Adrenergic, alpha-2DexmedetomidineLeukocyteOutcome

Identifiers

PMID33933842
PMCPMC8324520
OpenAlexW3157038629

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.